Proteomics-driven cancer biomarker discovery: looking to the future
journal contributionposted on 12.08.2021, 06:41 by Richard SimpsonRichard Simpson, OK Bernhard, David GreeningDavid Greening, RL Moritz
Availability of a suite of biomarkers for early detection, stratification into distinct subtypes, and monitoring progression or response to therapy promises significant improvements in clinical outcomes for cancer patients. However, despite the recent progress in proteomics technologies based on mass spectrometry (MS), discovery of novel clinical assessment tools has been slow. This is, partly due to the inherent difficulties in working with blood as the biospecimen for candidate discovery. A better understanding of the limitations of blood for comparative protein profiling and a better appreciation of the advantages of cancer tissue or cancer cell secretomes have the potential to greatly enhance the progress. Crown Copyright © 2008.
JournalCurrent Opinion in Chemical Biology
PublisherCURRENT BIOLOGY LTD
Rights StatementThe Author reserves all moral rights over the deposited text and must be credited if any re-use occurs. Documents deposited in OPAL are the Open Access versions of outputs published elsewhere. Changes resulting from the publishing process may therefore not be reflected in this document. The final published version may be obtained via the publisher’s DOI. Please note that additional copyright and access restrictions may apply to the published version.
Science & TechnologyLife Sciences & BiomedicineBiochemistry & Molecular BiologyBiophysicsLASER CAPTURE MICRODISSECTIONDIFFERENTIAL PEPTIDE DISPLAYLOW ABUNDANCE PROTEINSGEL-ELECTROPHORESISMASS-SPECTROMETRYLIQUID-CHROMATOGRAPHYQUANTITATIVE-ANALYSISCOLORECTAL CANCERSCONDITIONED MEDIAFLUORESCENT DYESCell Line, TumorBody FluidsHumansNeoplasmsBlood ProteinsProteomicsBiomarkers, TumorOrganic Chemistry